Moreover, recent studies have suggested that in the neoadjuvant setting, failure to achieve a pCR is clearly associated with worse long-term outcomes in TNBC and HER-2+ breast cancer but not in the majority of hormone receptor–positive breast cancers [7, 8]. Here, ERBB2 is linked to breast cancer.